MANZO MICHAEL P.

SEC source: 0001104659-21-100199 · tm2124160d3_4seq1.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,378

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2021.

SEC source: 0001104659-21-089446 · tm2121558d3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,443

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.78, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-077764 · tm2119042d2_4seq1.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,603

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.31, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-061948 · tm2115347d2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,758

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.36, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-048714 · tm2112624-2_4seq1.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,916

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.77 to $4.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-032764 · tm218853-2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,110

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.41 to $5.49, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011853 · tm215262-11_4seq1.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,302

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.35, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011853 · tm215262-11_4seq1.xml · derivative · entry 2

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-02-01

F3 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-21-000932 · tm211689-2_4seq1.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,292

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $4.85, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-133324 · tm2038041-2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,407

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

SEC source: 0001104659-20-120949 · tm2034888d1_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,498

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020.

SEC source: 0001104659-20-112302 · tm2032523-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,595

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.88 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-102298 · tm2030216d2_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,693

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020.

SEC source: 0001104659-20-090918 · tm2026743-2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,790

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020

SEC source: 0001104659-20-081225 · tm2024119-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,885

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020.

SEC source: 0001104659-20-069822 · tm2021837-1_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,982

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.1781, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-057471 · tm2018856d2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,076

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020.

SEC source: 0001104659-20-043262 · tm2014998d2_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,169

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.12, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-031497 · tm2012338d2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,291

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-022843 · tm209305-3_4.xml · derivative · entry 2

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2030-02-14

F2 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2021, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022843 · tm209305-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,421

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on February 1, 2021, and the remaining balance will vest monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-011330 · tm206871d3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,921

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020.

SEC source: 0001104659-20-001636 · tm201302-1_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,030

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.52, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-075131 · tm1926709d2_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,149

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.46 to $7.47, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-061123 · tm1922166-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.00, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001144204-19-048120 · tv530953_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,358

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2019 and 10/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.93 to $3.40, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.

SEC source: 0001144204-19-038333 · tv527076_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,147

SEC source: 0001144204-19-034765 · tv525231_4.xml · nonDerivative · entry 3

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,796

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.227 to $0.2403, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

SEC source: 0001144204-19-034765 · tv525231_4.xml · nonDerivative · entry 2

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,380

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2257 to $0.24, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

SEC source: 0001144204-19-034765 · tv525231_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,963

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.245, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001144204-19-005041 · tv512441_form4.xml · derivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-02-01

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2020, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-18-038193 · tv498482_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,546

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on July 10, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-18-012236 · tv487519_4.xml · derivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-02-28

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 28, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-17-033644 · v469460_4.xml · derivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-21

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-17-028875 · v467587_4.xml · derivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2027-05-18

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option became exercisable immediately upon grant.

SEC source: 0001144204-17-027562 · v467081_4.xml · derivative · entry 2

MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,285 shares

Expires 2017-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable immediately at the time of grant.

SEC source: 0001144204-17-027562 · v467081_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-006504 · v458600_4.xml · derivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-02-06

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 6, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.